Research programme: hepatitis B therapeutics - Enanta

Drug Profile

Research programme: hepatitis B therapeutics - Enanta

Alternative Names: Core inhibitors - Enanta; EP-027367; HBV therapeutics - Enanta

Latest Information Update: 16 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enanta Pharmaceuticals
  • Class Antivirals
  • Mechanism of Action Viral core protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 12 Apr 2018 Pharmacodynamics, safety and pharmacokinetics data from a preclinical study in Hepatitis B presented at The International Liver Congress 2018 (ILC-2018)
  • 11 Apr 2018 Updated pharmacodynamics data from preclinical trials in Hepatitis B presented at The International Liver Congress 2018 (ILC-2018)
  • 08 Aug 2016 Preclinical trials in Hepatitis B in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top